Global Preimplantation Genetic Diagnosis Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Preimplantation Genetic Diagnosis Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Preimplantation Genetic Diagnosis (PGD) is a technique used for detecting genetic defects in embryos developed through in vitro fertilization (IVF) before pregnancy. PGD involves performing tests on embryos to determine genetic abnormality. PGD is an alternative to current post conception diagnostic procedures.
Global Preimplantation Genetic Diagnosis market is projected to reach US$ 914 million in 2033, increasing from US$ 493 million in 2022, with the CAGR of 8.9% during the period of 2023 to 2033. Demand from Fertility Clinics and Research are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Preimplantation Genetic Diagnosis industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Preimplantation Genetic Diagnosis key companies include Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Perkinelmer, Inc., Coopersurgical, ABBott Laboratories, Natera, Inc., Rubicon Genomics and Oxford Gene Technology, etc. Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc. are top 3 players and held % share in total in 2022.
Preimplantation Genetic Diagnosis can be divided into Genetic Diagnosis and Genetic Screening, etc. Genetic Diagnosis is the mainstream product in the market, accounting for % share globally in 2022.
Preimplantation Genetic Diagnosis is widely used in various fields, such as Fertility Clinics and Research, etc. Fertility Clinics provides greatest supports to the Preimplantation Genetic Diagnosis industry development. In 2022, global % share of Preimplantation Genetic Diagnosis went into Fertility Clinics filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Preimplantation Genetic Diagnosis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Illumina, Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Perkinelmer, Inc.
Coopersurgical
ABBott Laboratories
Natera, Inc.
Rubicon Genomics
Oxford Gene Technology
Yikon Genomics
Scigene
Segment by Type
Genetic Diagnosis
Genetic Screening
Fertility Clinics
Research
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Preimplantation Genetic Diagnosis market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Preimplantation Genetic Diagnosis introduction, etc. Preimplantation Genetic Diagnosis Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Preimplantation Genetic Diagnosis market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Global Preimplantation Genetic Diagnosis market is projected to reach US$ 914 million in 2033, increasing from US$ 493 million in 2022, with the CAGR of 8.9% during the period of 2023 to 2033. Demand from Fertility Clinics and Research are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Preimplantation Genetic Diagnosis industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Preimplantation Genetic Diagnosis key companies include Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Perkinelmer, Inc., Coopersurgical, ABBott Laboratories, Natera, Inc., Rubicon Genomics and Oxford Gene Technology, etc. Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc. are top 3 players and held % share in total in 2022.
Preimplantation Genetic Diagnosis can be divided into Genetic Diagnosis and Genetic Screening, etc. Genetic Diagnosis is the mainstream product in the market, accounting for % share globally in 2022.
Preimplantation Genetic Diagnosis is widely used in various fields, such as Fertility Clinics and Research, etc. Fertility Clinics provides greatest supports to the Preimplantation Genetic Diagnosis industry development. In 2022, global % share of Preimplantation Genetic Diagnosis went into Fertility Clinics filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Preimplantation Genetic Diagnosis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Illumina, Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Perkinelmer, Inc.
Coopersurgical
ABBott Laboratories
Natera, Inc.
Rubicon Genomics
Oxford Gene Technology
Yikon Genomics
Scigene
Segment by Type
Genetic Diagnosis
Genetic Screening
Segment by Application
Fertility Clinics
Research
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Preimplantation Genetic Diagnosis market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Preimplantation Genetic Diagnosis introduction, etc. Preimplantation Genetic Diagnosis Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Preimplantation Genetic Diagnosis market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.